目的探讨微信小程序在结直肠癌化疗患者出院后化疗相关性不良反应(chemotherapy–induced nausea and vomiting,CINV)自我管理及延续性护理中的应用与体会。方法采用非同期对照研究设计,选取2018年10月至2019年12月在中国科学院大学附...目的探讨微信小程序在结直肠癌化疗患者出院后化疗相关性不良反应(chemotherapy–induced nausea and vomiting,CINV)自我管理及延续性护理中的应用与体会。方法采用非同期对照研究设计,选取2018年10月至2019年12月在中国科学院大学附属肿瘤医院化疗的结直肠癌患者200例,2018年10月至2019年5月,采用传统纸质问卷随访,发放问卷162份,以回收有效问卷100例患者作为对照组,断档2019年8月~12月,采用微信小程序随访,系统推送问卷124份,以回收有效问卷100例患者作为观察组。比较两组患者CINV的发生情况及对医务人员的满意度情况。结果使用微信小程序随访后,患者CINV记录准确率及对医务人员的满意度均有提高,差异均有统计学意义(P<0.05)。结论通过微信小程序随访,能更准确、及时地了解患者对于CINV的发生情况,若发生严重不良反应,医护能通过私信进行指导干预,提高患者化疗后的生活质量及对医务人员的满意度,微信小程序随访更容易被患者接受,特别是年轻患者,值得临床应用。展开更多
目的：研究参附注射液对晚期结直肠癌化疗患者血细胞的影响。方法选取2011年06月~2012年11月晚期结直肠癌患者59例,按随机数字表法分组,两组直肠癌患者均接受化疗,在化疗过程中,为对照组患者应用氯化钠注射液,为实验组患者应用参附注射...目的：研究参附注射液对晚期结直肠癌化疗患者血细胞的影响。方法选取2011年06月~2012年11月晚期结直肠癌患者59例,按随机数字表法分组,两组直肠癌患者均接受化疗,在化疗过程中,为对照组患者应用氯化钠注射液,为实验组患者应用参附注射液,统计两种注射液对患者血细胞的影响。结果比较两组红细胞计数、T淋巴细胞亚群,具有可比性（P〉0.05）,此外,两组白细胞计数、血小板计数差异具有统计意义[（3.23±177;1.12）±215;109 VS （2.99±177;0.79）±215;109,（187.31±177;32.21）±215;109 VS （201.15±177;3.42）±215;109, P〈0.05]。结论为晚期结直肠癌化疗患者应用参附注射液,可在一定程度上稳定白细胞、红细胞及血小板,参附注射液具有较高的应用价值,值得进一步推广。展开更多
AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced o...AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal.展开更多
文摘目的探讨微信小程序在结直肠癌化疗患者出院后化疗相关性不良反应(chemotherapy–induced nausea and vomiting,CINV)自我管理及延续性护理中的应用与体会。方法采用非同期对照研究设计,选取2018年10月至2019年12月在中国科学院大学附属肿瘤医院化疗的结直肠癌患者200例,2018年10月至2019年5月,采用传统纸质问卷随访,发放问卷162份,以回收有效问卷100例患者作为对照组,断档2019年8月~12月,采用微信小程序随访,系统推送问卷124份,以回收有效问卷100例患者作为观察组。比较两组患者CINV的发生情况及对医务人员的满意度情况。结果使用微信小程序随访后,患者CINV记录准确率及对医务人员的满意度均有提高,差异均有统计学意义(P<0.05)。结论通过微信小程序随访,能更准确、及时地了解患者对于CINV的发生情况,若发生严重不良反应,医护能通过私信进行指导干预,提高患者化疗后的生活质量及对医务人员的满意度,微信小程序随访更容易被患者接受,特别是年轻患者,值得临床应用。
文摘目的：研究参附注射液对晚期结直肠癌化疗患者血细胞的影响。方法选取2011年06月~2012年11月晚期结直肠癌患者59例,按随机数字表法分组,两组直肠癌患者均接受化疗,在化疗过程中,为对照组患者应用氯化钠注射液,为实验组患者应用参附注射液,统计两种注射液对患者血细胞的影响。结果比较两组红细胞计数、T淋巴细胞亚群,具有可比性（P〉0.05）,此外,两组白细胞计数、血小板计数差异具有统计意义[（3.23±177;1.12）±215;109 VS （2.99±177;0.79）±215;109,（187.31±177;32.21）±215;109 VS （201.15±177;3.42）±215;109, P〈0.05]。结论为晚期结直肠癌化疗患者应用参附注射液,可在一定程度上稳定白细胞、红细胞及血小板,参附注射液具有较高的应用价值,值得进一步推广。
基金Supported by The companies Pfizer and Roche provided partial support for the study and data monitoring
文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal.
